FilingIndex
6-KThe Wire

Alpha Tau Medical Ltd. files 6-K

Filed Apr 23, 2026 · 3mo ago · Accession 0001213900-26-046897

Plain English

Alpha Tau Medical Ltd. announced two significant clinical trial updates: the successful treatment of the first pancreatic cancer patient in Europe using Alpha DaRT® in the ACAPELLA trial, and FDA approval to expand the IMPACT trial to include pancreatic cancer patients receiving specific chemotherapy.

Read the original on SEC.gov ↗
Filing details
Ticker
DRTS
CIK
1871321
Form type
6-K
Filing date
Apr 23, 2026
Report date
Apr 23, 2026
Document
ea0287451-6k_alphatau.htm
Size
50 KB